Processing

Please wait...

Settings

Settings

Goto Application

1. JP2020090532 - A3 ADENOSINE RECEPTOR LIGANDS FOR TREATING ECTOPIC FAT ACCUMULATION

Office
Japan
Application Number 2020020917
Application Date 10.02.2020
Publication Number 2020090532
Publication Date 11.06.2020
Grant Number 6990934
Grant Date 09.12.2021
Publication Kind B1
CPC
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
Applicants CAN-FITE BIOPHARMA LTD
キャン-ファイト バイオファーマ リミテッド
Inventors PNINA FISHMAN
フィッシュマン,プニナ
SHIRA COHEN
コーエン,シラ
Agents 特許業務法人北青山インターナショナル
Priority Data 242723 23.11.2015 IL
Title
(EN) A3 ADENOSINE RECEPTOR LIGANDS FOR TREATING ECTOPIC FAT ACCUMULATION
(JA) 異所性脂肪蓄積治療用A3アデノシン受容体リガンド
Abstract
(EN)

PROBLEM TO BE SOLVED: To provide an A3AR ligand that reduces ectopic fat accumulation, especially in fatty liver, use of A3AR ligands for producing pharmaceutical compositions to reduce such fat accumulation, methods for treating symptoms associated with fat accumulation using the ligand, and a kit for treating symptoms associated with ectopic fat accumulation which comprises a pharmaceutical composition comprising the ligand and an instruction for using the pharmaceutical composition.

SOLUTION: In one embodiment, use of 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluron amide (Cl-IB-MECA, CF102) in treating fatty liver, in particular non alcoholic fatty liver disease (NAFLD), is provided.

SELECTED DRAWING: None

COPYRIGHT: (C)2020,JPO&INPIT


(JA)

【課題】本開示は、特に脂肪肝における、異所性脂肪蓄積を低減するAARリガンドに関する。また、本開示によれば、このような脂肪蓄積を低減する医薬組成物の製造用AARリガンドの使用、このリガンドを使用した脂肪蓄積に伴う症状を治療する方法、及び、異所性脂肪蓄積に関連する症状を治療するための、前記リガンドを含む医薬組成物と、当該医薬組成物の使用のための指示書、とを具えるキット、を提供する。
【解決手段】一の実施例において、本開示は、脂肪肝、特に、非アルコール性脂肪性肝臓疾患(NAFLD)の治療用の、2−クロロ−N−(3−ヨードベンジル)−アデノシン−5’−N−メチルウロナミド(Cl−IB−MECA、CF102)の使用を提供している。
【選択図】なし


Related patent documents
RSP-2021/0079This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.